Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Advanced or metastatic non-small-cell lung cancer (NSCLC) has poor long-term survival rates with current palliative chemotherapy.
• Cytotoxic drug combinations have not significantly improved outcomes beyond platinum doublets.
• Molecular targeted drugs show potential for long-term disease control by inhibiting cancer progression pathways.

Purpose of the Study:

• To review the current state-of-the-art research in targeted therapy for non-small-cell lung cancer (NSCLC).
• To discuss the efficacy of various targeted agents in unselected and selected NSCLC patient populations.
• To highlight emerging targets and novel drugs for NSCLC treatment.

Main Methods:

• Review of current literature on targeted therapies in advanced NSCLC.
• Analysis of clinical trial data for EGFR inhibitors, monoclonal antibodies, antiangiogenic strategies, and novel agents.
• Identification of key signaling pathways and molecular aberrations targeted in NSCLC.

Main Results:

• EGFR inhibitors show significant benefit in patients with EGFR mutations.
• Novel targeted therapies against insulin-like growth factor 1 receptor and EML4-ALK fusion proteins demonstrate promising activity.
• Aberrations in RAS/RAF/MEK, PI3K/AKT/mTOR, and MET kinase pathways are crucial targets, especially in resistant NSCLC.

Conclusions:

• Targeted therapies represent a significant advancement in treating advanced NSCLC, particularly in molecularly selected patient groups.
• Ongoing research into novel molecular targets and drugs is crucial for improving long-term survival in NSCLC.
• Personalized medicine approaches targeting specific genetic alterations are key to optimizing NSCLC treatment outcomes.